Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Codiak BioSciences, Inc. (CDAK)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.6855+0.0254 (+3.85%)
At close: 04:00PM EST
0.7100 +0.02 (+3.57%)
After hours: 06:02PM EST
Advertisement

Codiak BioSciences, Inc.

35 Cambridge Park Drive
Suite 500
Cambridge, MA 02140
United States
617 949 4100
https://www.codiakbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees102

Key Executives

NameTitlePayExercisedYear Born
Dr. Douglas Edward Williams Ph.D.Pres, CEO & Director970.77kN/A1958
Ms. Linda Cathavina Bain CPACFO & Treasurer602.54kN/A1970
Dr. Sriram Sathyanarayanan Ph.D.Chief Scientific Officer502.17kN/A1972
Dr. Konstantin Konstantinov Ph.D.Chief Technology OfficerN/AN/A1958
Mr. Christopher J. M. TaylorVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Yalonda HowzeExec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec.N/AN/A1972
Ms. Nicole BarnaSr. VP of HRN/AN/A1974
Dr. David J. Mauro M.D., Ph.D.Chief Medical OfficerN/AN/A1965
Dr. Benny Sorensen M.D., Ph.D.Member of Scientific Advisory Board & ConsultantN/AN/A1974
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Codiak BioSciences, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 7. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement